Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 5/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096300 | 0.84 | P2RX7 (0.37) | NPBWR1P2RX7LRRK2APPABCG2 | |
| SCHEMBL4105507 | 0.82 | GRIN1 (0.42) | NPBWR1GRIN1GRIN2BRAF1AKR1C3 | |
| SCHEMBL4102442 | 0.80 | GRIN1 (0.39) | NPBWR1GRIN1GRIN2B | |
| SCHEMBL4101100 | 0.66 | P2RX7 (0.38) | NPBWR1P2RX7LRRK2APP | |
| SCHEMBL15606507 | 0.62 | MEN1 (0.41) | NPBWR1GRIN1GRIN2BP2RX7AKR1C3 | |
| SCHEMBL22775009 | 0.61 | GRIN1 (1.00) | GRIN1GRIN2B | |
| SCHEMBL4091530 | 0.60 | MAP4K1 (0.38) | — | |
| Hydrochloric Acid SCHEMBL22775310 | 0.60 | GRIN1 (0.98) | GRIN1GRIN2B | |
| Hydrochloric Acid SCHEMBL29525058 | 0.60 | GRIN1 (0.98) | GRIN1GRIN2B | |
| SCHEMBL4090436 | 0.60 | SYK (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | NPBWR1 128/4885GRIN1 193/4885GRIN2B 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.